BenevolentAI
molecular design in structure based design virtual screening and machine learning we combine deep in drug discovery with innovative techniques in structure based design virtual screening and machine learning highly experienced drug discovery team with a proven track record of taking nascent ideas and delivering drugs to the clinic and tools impacting all stages of a drug from target selection through to candidate nomination empowering chemists to design better drugs in cycles candidate drugs delivered in as little as years from inception compared to year industry standard target hit cation hit expansion lead candidate seeking | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
17 of 42
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io